Pemvidutide vs Semaglutide

Pemvidutide is an experimental GLP-1 and glucagon dual-action drug still in development, while semaglutide (sold as Ozempic, Wegovy, or Rybelsus) is an FDA-approved GLP-1-only treatment already used for type 2 diabetes, obesity, chronic kidney disease, and reducing cardiovascular risk. The main practical difference is that semaglutide is available now in several brand-name forms, whereas pemvidutide has no approved uses yet. Semaglutide is taken by injection or pill, while pemvidutide’s dosing method hasn’t been finalized.

AI summary of the sources below.